In a world where pricing decisions are increasingly interconnected, a risk for healthcare leaders to consider is lagging evidence.​ ...

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone. IRP is a government price-control mechanism utilized worldwide, where a country ...

In 2015, the first biosimilar (Zarxio; Sandoz) was launched in the United States (US), providing an alternative to the originator product Neupogen (filgrastim; Amgen) for the treatment of severe ...

This approval provides patients with a new generic option for the folate analog metabolic inhibitor, which is used to treat ...

Predicting Bioequivalence During Generic Drug Formulation. Small variations in formulation can affect bioequivalence. However ...